key: cord-0882709-di1k81oj
authors: Visser, Chantal; Swinkels, Maurice; van Werkhoven, Erik D.; Croles, F. Nanne; Noordzij-Nooteboom, Heike; Eefting, Matthijs; Last-Koopmans, Suzanne M.; Idink, Cecile; Westerweel, Peter E.; Santbergen, Bart; Jobse, Pieter A.; Baboe, Fazil; te Boekhorst, Peter A.W.; Leebeek, Frank W.G.; Levin, Mark-David; Kruip, Marieke J.H.A.; Jansen, A. J. Gerard
title: COVID-19 vaccination in patients with immune thrombocytopenia
date: 2021-12-25
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021006379
sha: 4b0bf935463de511e24ce7bdfd435a0903fdf6e0
doc_id: 882709
cord_uid: di1k81oj

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelet count and increased bleeding risk. COVID-19 vaccination has been described as risk factor for de novo ITP, but the effects of COVID-19 vaccination in patients with ITP are unknown. Our aims were to investigate the effects of COVID-19 vaccination in ITP patients on platelet count, bleeding complications and ITP exacerbation (any of: ≥50% decline in platelet count; or nadir platelet count <30×109/L with >20% decrease from baseline; or use of rescue therapy). Platelet counts of ITP patients and healthy controls were collected immediately before, 1 and 4 weeks after first and second vaccination. Linear mixed-effects modelling was applied to analyze platelet counts over time. We included 218 ITP patients (50.9% female, mean age 55 years and median platelet count of 106×109/L) and 200 healthy controls (60.0% female, mean age 58 years and median platelet count of 256×109/L). Platelet counts decreased by 6.3% after vaccination. We observed no difference in decrease between the groups. Thirty ITP patients (13.8%, 95%CI 9.5%-19.1%) had an exacerbation and 5 (2.2%, 95%CI 0.7%-5.3%) suffered from a bleeding event. Risk factors for ITP exacerbation were platelet count <50×109/L (OR 5.3, 95%CI 2.1-13.7), ITP treatment at time of vaccination (OR 3.4, 95%CI 1.5-8.0) and age (OR 0.96 per year, 95%CI 0.94-0.99). Our study highlights safety of COVID-19 vaccination in ITP patients and importance of close monitoring platelet counts in a subgroup of ITP patients. ITP patients with exacerbation responded well on therapy.

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelet count and increased bleeding risk. COVID-19 vaccination has been described as risk factor for de novo ITP, but the effects of COVID-19 vaccination in patients with ITP are unknown. Our aims were to investigate the effects of COVID-19 vaccination in ITP patients on platelet count, bleeding complications and ITP exacerbation (any of: ≥50% decline in platelet count; or nadir platelet count <30x10 9 /L with >20% decrease from baseline; or use of rescue therapy). Platelet counts of ITP patients and healthy controls were collected immediately before, 1 and 4 weeks after first and second vaccination. Linear mixed-effects modelling was applied to analyze platelet counts over time. We included 218 ITP patients (50.9% female, mean age 55 years and median platelet count of 106x10 9 /L) and 200 healthy controls (60.0% female, mean age 58 years and median platelet count of 256x10 9 /L).

Platelet counts decreased by 6.3% after vaccination. We observed no difference in decrease between the groups. Thirty ITP patients (13.8%, 95%CI 9.5%-19.1%) had an exacerbation and 5 (2.2%, 95%CI 0.7%-5.3%) suffered from a bleeding event.

Risk factors for ITP exacerbation were platelet count <50x10 9 [1] [2] [3] [4] Reports of serious adverse events, including vaccine associated immune thrombocytopenia (ITP), thrombosis, and the rare occurrence of vaccine induced immune thrombotic thrombocytopenia (VITT), has led to a restrictive use of the ChAdOx1-S and Ad26.COV2.S vaccine. 5, 6 Immune thrombocytopenia is an acquired autoimmune disorder characterized by low platelet count (<100x10 9 /L) resulting from platelet destruction and impaired platelet production, leading to increased bleeding risk. 7 ITP is likely to rise from defective immune tolerance in addition to a possible triggering event. 7 COVID-19 infection has recently been identified as risk factor for ITP development 8 and a large population study showed a small increased risk of de novo ITP after ChAdOx1-S vaccine, but not after BNT162b2 vaccine. 9 These findings illustrate that immunological events like infection and vaccination in the COVID-19 pandemic could be an important risk factor in the development and exacerbation of ITP.

Exacerbation of thrombocytopenia in ITP patients after COVID-19 vaccination has been described in retrospective studies, but a systematic evaluation of platelet counts over time is missing. [10] [11] [12] [13] Therefore, it is still unclear how COVID-19 vaccination affects ITP patients over time, if and when thrombocytopenia develops and when they are at risk for bleeding.

To gain a better understanding of the effect of COVID-19 vaccination in ITP patients, we systematically monitored platelet counts, bleeding events and ITP exacerbations in routine clinical practice.

We conducted a multicenter observational study across nine participating hospitals in The Netherlands. The study was designed and conducted in accordance with the Declaration of Helsinki. The medical ethical committee of Erasmus MC and the local research committees approved the study protocol and amendments (MEC-2021-0238). Erasmus MC was sponsor, served as coordinating center, and was responsible for maintenance of the database, validation and analyses of data, and trial coordination.

Adult patients historically diagnosed with ITP according to Rodeghiero 

Primary objective was to study platelet dynamics in ITP patients after COVID-19 vaccination. Secondary outcomes were symptomatic bleeding (defined as bleeding of WHO grade ≥2), exacerbation of ITP (defined as development of any of the following: a) ≥50% decline in platelet count compared to baseline; b) >20% decline in platelet count compared to baseline and a platelet nadir <30x10 9 /L; or c) receiving rescue medication). Rescue medication was defined as treatment change by discretion of the treating physician, i.e. switch to other ITP medication, start of new ITP medication, addition of concomitant ITP medication or intensification of current ITP treatment, all independently of change in platelet count) and vaccine specific and non-specific adverse events. Finally, risk factors for ITP exacerbation were studied.

Descriptive statistics were expressed as median and interquartile range (IQR), mean and standard deviation (SD) or as counts with percentages. Characteristics of ITP patients and healthy controls were compared using Fisher's test or Wilcoxon's rank sum test with continuity correction. To identify the effect of COVID-19 vaccination over time while taking into account the intra-subject variability, a linear mixed-effects model was applied on log-transformed platelet count. After log transformation, platelet count had a closer to normal distribution, allowing better model fit. The exponentiated model coefficients can be interpreted as ratios of the geometric means and percentage differences. A random intercept per patient was included. In this model, time was considered a grouped variable and no interaction between time and ITP status was included due to lack of interaction (p=0.78 of the interaction term). We corrected the model using fixed effects for age, sex, duration of ITP, presence of any treatment at start of vaccination, receiving any previous ITP treatment, splenectomy, rescue medication and treatment in an academic center.

Rescue medication was treated as a time-varying covariate. It was set to 0 at start and 1 after first date of rescue medication. A Friedman test was performed in the subgroups of ITP patients grouped by baseline platelet count with steps of 50x10 9 /L platelets. The 95% confidence intervals of the crude percentages of patients with exacerbation and bleeding were calculated using Clopper-Pearson method. A logistic regression model was created to identify risk factors for exacerbation. All other statistical analyses were performed with IBM SPSS statistics version 25 and R version 4.1.1. with package Ime4.

We included 218 ITP patients (50.9% female) aged 55 (17) years and 200 healthy controls (60.0% female) aged 58 (13) years between February 1 st and July 16 th 2021 (Table 1 ). All healthy controls received the same vaccine (mRNA-1273 vaccines) 15 Healthy controls and ITP patients had similar baseline characteristics, except for small difference in mean age (58.2 and 55.2 years respectively, p=0.047) and lower median baseline platelet count (256x10 9 /L and 106x10 9 /L respectively, p <0.001) ( Table 1) . One hundred ninety six (89.9%) ITP patients had primary ITP for a median duration (IQR) of 5.8 (10.6) years. One hundred thirty-six (62.4%) patients had chronic ITP and 69 (31.7%) were in remission. Sixty-four (29.5%) ITP patients were receiving ITP treatment at time of first vaccination. Sixteen (7.3%) ITP patients used rescue medication in the previous 6 months prior COVID-19 vaccination.

A decrease in platelet count during our study was observed in 55.0% (N=120) of the ITP patients and in 63.0% (N=126) of the healthy controls ( Figure 1A ). In ITP patients grouped by baseline platelet count, no significant difference in decrease of platelet counts over time was found, except for ITP patients with baseline platelet counts of >150x10 9 /L ( Figure 1B) . A large variability in platelet counts was observed across ITP patients (intra-class correlation 0.75; Figures 2A-C).

In the mixed-effects analysis, a significant decrease in platelet count of 6.3% was found 4 weeks after the second vaccination compared to baseline ( Figure 3 , Table   S1 ). We corrected for age, sex, duration of ITP, current treatment, receiving any prior ITP treatment, splenectomy, rescue medication and treatment in an academic center. We observed no difference in decrease between the groups.

Factors significantly associated with decreased platelet counts were longer duration of ITP (defined as years between ITP diagnosis and COVID-19 vaccination) and presence of current treatment; in contrast, previous splenectomy was associated with increased platelet counts ( Figure 3 , Table S1 ).

Thirty (13.8%, 95%CI 9.5%-19.1%) ITP patients showed an exacerbation during the study period (Table 1) . Eighteen (8.3%) ITP patients had a ≥50% decline in platelet count compared to baseline, 18 (8.3%) ITP patients had a >20% decline in platelet count compared to baseline and platelet nadir <30x10 9 /L and 15 (6.9%) ITP patients received rescue medication after COVID-19 vaccination ( Table 2) . Eleven (36.7%) of these 30 ITP patients needed rescue medication 6 months prior COVID-19 vaccination compared to 5 (2.7%) of the ITP patients without exacerbation ( Table 1) .

Out of the 30 patients with exacerbation, there were 16 who experienced it after their first vaccination of which 3 did not receive the second vaccination. Individual platelet counts of ITP patients with rescue medication and significant decrease in platelet count are shown in Figures S2A and B respectively. Six (2.8%) patients started with ITP treatment after COVID-19 vaccination of whom three received glucocorticoids only, one glucocorticoids with intravenous immunoglobulin (IVIG), one IVIG and one eltrombopag. Seven (3.2%) patients required intensification or switch of current treatment consisting of romiplostim (N=4) and eltrombopag (N=3). Two patients received additional IVIG (Table 2) .

Rescue medication resulted in complete response in 7 (46.7%) patients and (partial) response in 2 (13.3%) patients. One patient (6.7%) did not respond to rescue medication and five (33.3%) patients had no recorded response.

Bleeding complications occurred in 5 (2.3%) ITP patients and in 0 (0.0%) healthy controls ( Table 2 ). The first patient experienced two bleeding complications after the first COVID-19 vaccination. Two weeks after the COVID-19 vaccination, the patient experienced hematuria with a platelet count of <3x10 9 /L. The second bleeding was a vitreous hemorrhage and occurred three weeks after the first COVID-19 vaccination, with a platelet count of 7x10 9 /L. The second patient experienced several bleedings during the study period with epistaxis, oral mucosal bleeding and urogenital bleeding. This patient had a baseline platelet count of <3x10 9 /L and received red blood cell transfusion and additional IVIG due to a severe epistaxis episode. The third patient had a bleeding event after elective vascular surgery and received red blood cell transfusion in combination with platelet transfusion. The platelet count was 75x10 9 /L and the patient did not experience any drop in platelet count after COVID-19 vaccination. The fourth patient had a spontaneous cerebellar bleeding three weeks after the first vaccination with a platelet count of 104x10 9 /L. This patient did not experience a drop in platelet count after COVID-19 vaccination. The patient was treated with additional platelet transfusion and corticosteroids. The fifth patient had a fatal esophageal bleeding 2 weeks after the first COVID-19 vaccination. This patient experienced a drop in platelet count to 14x10 9 /L after COVID-19 vaccination for which the dosage of romiplostim was increased. However, the patient had a normal platelet count of 175x10 9 /L at the moment of bleeding. Despite endoscopic intervention and additional platelet transfusion, the patient died due to ongoing bleeding.

Most common reported side effects after COVID-19 vaccination in ITP patients were local tenderness and swelling at site of vaccination (15, 29 .4%), myalgia and arthralgia (13, 25.5%). Fever was more often reported after second vaccination (Table S2) .

Risk factors for exacerbation of ITP after vaccination were baseline platelet counts less than 50x10 9 /L (OR 5.33, 95%CI 2.07-13.73), ITP treatment at start of COVID-19 vaccination (OR 3.44, 95% CI 1.47-8.04) and younger age (OR 0.96 per year, 95%CI 0.94-0.99) (Table S3) . Even though longer duration of ITP was associated with a decrease in platelet counts over the entire study, in our logistic regression model it did not increase risk of exacerbation. Type of vaccine was not associated with risk of exacerbation, but the sample size was possibly too small to detect differences between groups. Presence of antiplatelet antibodies was also not associated with exacerbation risk. However, presence of antiplatelet antibodies was recorded in only 4.6% of ITP patients, so our sample size may have been too small to detect differences.

In this study, we systematically investigated the effects of COVID-19 vaccination on platelet count in a large study of ITP patients compared to healthy controls. Only 3 out of 218 patients experienced problems after first vaccination prohibiting completion of the series. COVID-19 vaccination led to a significant decrease in platelet counts of 6.3% in both ITP patients and healthy controls. Of the ITP patients, 13 .8% showed an exacerbation following vaccination. Risk factors for exacerbation were baseline platelet count <50x10 9 /L, having ITP treatment at start of COVID-19 vaccination and/or age. Nearly all ITP patients had a (complete) response after rescue medication.

Thrombocytopenia (<100x10 9 /L) after vaccination has been described in children, with an incidence rate of 0.087-2.6 per 100.000 doses. 16 After COVID-19 vaccination in adults, thrombocytopenia has been reported with an incidence rate of 1.13-1.33 per 100.000 ChAdOx1-S doses. 9, 17, 18 In our study, 63% of healthy controls experienced decreased platelet counts four weeks after second vaccination, with only one (0.5%) with platelet count <100x10 9 /L.

In two small studies a decrease in platelet counts has been reported in 12-32% of the ITP patients after COVID-19 vaccination. 10, 11 This is in line with our reported decrease of platelet count in 55% ITP patients after COVID-19 vaccination. In contrast, a study of 92 ITP patients who mostly received the BNT162b2 vaccine, did not observe decreased platelet count after first and second vaccination. 12 In our mixed-effects model, we did observe a significant decrease of platelet counts of 6.3% in ITP patients after COVID-19 vaccination. As there is a high degree of interand intra-individual variability in platelet counts over time, we systemically measured patients over a longer observation period and corrected for inter-and intra-individual variability. We hypothesize that this systematic approach to monitor platelet count is essential to draw conclusions about platelet count changes following COVID-19 vaccination.

In our study, 13.8% of ITP patients had exacerbation of ITP, defined as development of any of the following: a) ≥50% decline in platelet count compared to baseline; b) >20% decline in platelet count compared to baseline and a platelet nadir <30x10 9 /L or c) receiving rescue medication. Other observational studies found comparable incidences between 12 to 25%. [11] [12] [13] . The amount of patients needing rescue medication was 6.9% in our study compared to 8.7% in the study of Crickx, et al. 12 In other autoimmune diseases, exacerbation of symptoms after COVID-19 vaccination has anecdotally been described, with rapid remission after glucocorticoids. 19, 20 However, in a single center study of 26 patients with chronic inflammatory diseases, no patients experienced disease flare. 21 Furthermore, a large cohort study showed no significant difference of exacerbation of autoimmune rheumatic disease (AIRD) after COVID-19 vaccination compared to non-AIRD rheumatic disease. 23 From our current understanding, we speculate that ITP similarly stems from a propensity to auto-immunity in combination with a triggering event such as infection or vaccination. 7 Intriguingly, in our systematic evaluation of platelet counts in ITP patients and healthy individuals, we found that both groups had significantly decreased platelet counts as a result of COVID-19 vaccination. This would suggest that exacerbation or development of thrombocytopenia because of (COVID- 19) vaccination might be unrelated to ITP, evidenced by the fact that we could not find an interaction between platelet counts over time and whether a subject had ITP. This observation is also underlined by the high degree of inter-individual variability in both ITP patients and healthy controls, suggesting no universal mechanism leading to lower or higher platelet counts. We also did not find a correlation between platelet counts and anti-SARS-CoV-2 IgG levels in the healthy controls (data not shown),

suggesting that, at least in healthy individuals, changes in platelet count are unrelated to vaccine response. On the other hand, we did find a significant negative association between platelet counts and ITP duration as well as between platelet counts and current ITP treatment. Also, ITP patients with exacerbation needed more frequent rescue medication prior to COVID-19 vaccination compared to ITP patients without exacerbation. These data may suggest that the hardest-to-treat, chronic ITP patients are more susceptible to develop thrombocytopenia after vaccination in comparison to a group currently not requiring treatment for ITP. Additionally, previous splenectomy was positively associated with platelet counts over time, signifying that this potential lack of acute immune response is directly favorable for platelet counts in these individuals. To summarize, it remains unclear if COVID-19 vaccination has a differential effect on ITP patients and healthy controls. Our associative findings warrant further investigation to firmly establish whether ITP patients are more prone to platelet count changes due to COVID-19 vaccination.

Our study aimed to provide better understanding of the effect of COVID-19 vaccination in ITP patients. In doing so, strengths of this study are the prospective and systematically evaluation of real-world data on platelet counts, bleeding complications and need for rescue medications in over 200 ITP patients.

Furthermore, we used a healthy control group to interpret results of ITP patients accordingly. There are also some limitations. First, almost all ITP patients received mRNA vaccine, so caution is warranted to generalize our results to other vaccines.

Still, mRNA vaccines are the most frequently used globally, with >80% of European and >90% of USA vaccine recipients inoculated with mRNA vaccines. 23,24 . One ITP patient received the adenoviral vector vaccine (ChAdOx1-S vaccine) without any significant changes in platelet count. Although thrombocytopenia after COVID19 vaccination is mostly described after ChAdOx1-S vaccination, conclusions cannot be made for ChAdOx1-S vaccination in ITP patients. 9 Secondly, even though we cannot exclude exacerbation after COVID-19 vaccination due to a natural course of ITP, half of the ITP patients with exacerbation did not use ITP treatment before COVID-19 vaccination. In these patients, COVID-19 vaccination seems to be a plausible cause of exacerbation. Thirdly, we did not measure anti-SARS-CoV-2 IgG levels in ITP patients as a measure of vaccine response, so no firm conclusions can be made about the direct effect of COVID-19 vaccination on platelet count. However, no association was seen between platelet count and antibody levels in healthy controls.

Finally, platelet count and bleeding complications of healthy controls were obtained from the RECOVAC IR study. As bleeding complications was not a primary outcome in this study, underestimation of bleeding complication might have occurred, although bleeding scores were similar, e.g. WHO criteria CTC grade 2 or more. Also, the RECOVAC-IR study did not measure platelet count one week after each COVID-19 vaccination. A temporary decrease in platelet count may be missed in healthy volunteers. However, we did observe in contrast an increase in overall platelet count in ITP patients one week after first and second vaccination.

To conclude, our study highlights safety of COVID-19 vaccination in patients with ITP and importance of close monitoring of platelet counts in a subgroup of ITP patients.

ITP patients with an exacerbation responded well on therapy. 

For original data, please contact a.j.g.jansen@erasmusmc.nl # Exacerbation is defined as the development of any of the following: a) ≥50%

decline in platelet count compared to baseline; b) >20% decline in platelet count compared to baseline and a platelet nadir <30x10 9 /L or c) use of rescue medication.

Rescue medication was defined as any treatment change by discretion of the treating physician, i.e. switch to other ITP medication, start of new ITP medication, addition of concomitant ITP medication or intensification of current ITP treatment. ** Exacerbation is defined as the development of any of the following: a) ≥50%

decline in platelet count compared to baseline; b) >20% decline in platelet count compared to baseline and a platelet nadir <30x10 9 /L or c) use of rescue medication.

Rescue medication was defined as any treatment change by discretion of the treating physician, i.e. switch to other ITP medication, start of new ITP medication, addition of concomitant ITP medication or intensification of current ITP treatment. 

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

Emerging Concepts in Immune Thrombocytopenia

COVID-19-associated immune thrombocytopenia

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Platelet Disorder Support Association. Results from the ITP Natural History Study

Exacerbation of immune thrombocytopenia following COVID-19 vaccination

Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia

SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients

Sep 29:blood.2021013411

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant

Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine

COVID-19 vaccination: possible short-term exacerbations of oral mucosal diseases

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey